AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.

(2017) G. Emons et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer

(2011) Jacob Mathew et al.   CURRENT OPINION IN ONCOLOGY

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer

(2011) Stephen V Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists

(2010) S. V. Liu et al.   CLINICAL CANCER RESEARCH

378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany

(2010) G. Emons et al.   EJC SUPPLEMENTS

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors

(2010) Günter Emons et al.   GYNECOLOGIC ONCOLOGY

Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors

(2010) Andrew V. Schally et al.   Current Drug Delivery

Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152

(2009) Günter Emons et al.   NEUROENDOCRINOLOGY